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Abstract: Overactive bladder is a dreadful syndrome that affects a considerable number of
patients. Antimuscarinics are the mainstay of pharmacotherapy for this condition. Transdermal
(TD) oxybutynin (OXY) bypasses the first-pass metabolism and reduces the formation of N-
desethyloxybutynin, a compound believed to be associated with anticholinergic side effects.
The 3.9mg matrix TD system is applied twice weekly and transports OXY directly into the
systemic circulation. The patch can be applied to abdomen, buttock, and hip, and provides
continuous OXY delivery that minimizes peak and trough fluctuations in plasma levels. In
clinical trials, TD and oral OXY produced a significant reduction in incontinence episodes,
with no difference between oral and TD treatments. In addition, TDOXY was similar to
tolterodine, and it produced a significant improvement in the number of urinary incontinence
episodes, complete continence, and urodynamic and quality of life parameters compared with
placebo. The incidence of anticholinergic adverse events with TDOXY was similar to placebo.
Most common adverse events were mild–moderate skin reactions. Treatment satisfaction survey
suggested patients’ preference to use the TD system in the future. Counseling on healthy skin
care and appropriate product use can enhance patients’ knowledge about TDOXY for overactive
bladder treatment.
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Introduction
Overactive bladder (OAB) is defined as urgency, with or without urge incontinence,
and usually with frequency and nocturia, in the absence of infection or other proven
etiology (Abrams et al 2002).
The National Overactive BLadder Evaluation (NOBLE) program examined the
prevalence and burden of OAB in the US population (Stewart et al 2003). The overall
prevalence of OAB was similar between men and women (16.0% and 16.9%,
respectively), and prevalence of urge incontinence increased with age. Overactive
bladder was associated with lower quality-of-life scores, higher depression scores,
and poorer quality of sleep.
In Europe, a population-based survey revealed a 16.6% overall prevalence of
OAB symptoms (Milsom et al 2001). Similar to the NOBLE study, the prevalence of
OAB symptoms increased with advancing age. Considering that only a few affected
individuals currently receive treatment, there is a substantial need for improvement
in the diagnosis and treatment of this condition.
Nonsurgical approach is the mainstay of OAB therapy, with fundamental
pharmacologic treatment based on muscarinic receptor antagonism. A recent meta-
analysis found that antimuscarinics confer quantifiable treatment benefit, in addition
to a significant improvement in quality of life (Chapple et al 2005). Differences in
the tolerability profiles of individual agents were thought to be of clinical significance
and have a significant influence on adherence and overall efficacy.Clinical Interventions in Aging 2006:1(2) 100
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Oxybutynin (OXY) is a competitive acetylcholine
antagonist that relaxes the bladder smooth muscle. In
patients with involuntary detrusor contractions, OXY
increases bladder capacity and volume to first detrusor
contraction, thus decreasing urinary urgency and frequency
of urination (Watson Pharma 2003). It is considered to be
the earliest and most well-accepted agent for the treatment
of OAB. However, anticholinergic side effects of orally
administered OXY, primarily dry mouth, may limit its
efficacy.
Pharmacokinetics
Oxybutynin is extensively metabolized, primarily by
CYP3A4, found mostly in the gut wall and liver. N-
desethyloxybutynin (DEO), one of the metabolites, is
believed to be associated with anticholinergic side effects
(Zobrist et al 2001). With oral administration, first-pass
metabolism of OXY reduces its bioavailability to 6% and
results in high levels of DEO (ratio to parent compound
11.9:1). In contrast, transdermally-delivered OXY is
associated with a bioavailability of approximately 80% and
low DEO levels .
The transdermal (TD) OXY system (Watson Pharma
2003) provides continuous and consistent delivery with
twice-a-week application (Figure 1). This matrix-type patch
system transports OXY directly into the systemic circulation
across intact skin.
Transdermal administration, unlike the oral route,
bypasses the first-pass metabolism and reduces the formation
of DEO (ratio to parent compound 1.3:1) (Watson Pharma
2003). This preserves unmetabolized OXY in the circulation
and results in greater systemic availability of the parent
compound. Patch delivery of 3.9mg/day produces OXY
plasma levels similar to 10mg/day of orally administered
extended-release OXY (Appell et al 2003). In addition, mean
saliva output was greater during TD than extended-release
oral treatment (15.7+9.3g vs 12.2+6.8g, respectively;
p=0.02), based on a standardized saliva-production assay
performed after achieving a pharmacologic steady state
(Appell et al 2003).
Pharmacokinetic studies in healthy volunteers
demonstrated bioequivalent OXY absorption with a 39cm
2
(3.9 mg/day) patch application to abdomen, buttock, and
hip (Zobrist et al 2003). In addition, a relationship between
various sizes of TD systems was examined. This is to be
expected since TDOXY is a matrix patch, with the
therapeutic compound being found within the adhesive layer,
and the adhesive surface area correlates directly with the
compound dosage. Mean steady state plasma concentrations
of OXY and DEO increased proportionally according to the
patch size, while DEO to OXY ratios showed similar
profiles.
Compared with oral administration, TD application
offers several potential ways to improve the therapeutic
value of OXY (Appell et al 2003; Zobrist et al 2003):
• avoidance of presystemic metabolism
• reducing exposure to the DEO metabolite
• greater saliva output
• continuous delivery that minimizes peak/trough
fluctuations in plasma levels that occur with intermittent
oral administration.
TD formulation
Oxybutynin transdermal system is a matrix-type TD system
containing OXY and triacetin (a skin permeation enhancer)
dissolved in an acrylic block–copolymer adhesive with a
surface area of 39cm
2 containing 36mg racemic OXY,
designed to continuously deliver OXY over a 3–4 day wear
period (Zobrist et al 2001).
Clinical experience
Efficacy
TD vs immediate release OXY (Davila et al 2001)
A total of 76 adults with history of urge or mixed urinary
incontinence were randomized to receive TD or oral OXY
for 6 weeks as part of a phase II clinical trial. All patients
were responders to previous oral immediate-release
anticholinergic therapy, with symptomatic improvement
during a minimum of 6 weeks of oral OXY. Patients had to
Figure 1 Transdermal oxybutynin system for overactive bladder.Clinical Interventions in Aging 2006:1(2) 101
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have at least 3 incontinent episodes daily, and a greater than
30% increase in urge incontinence episodes after a 2 week
washout from current treatments.
Bladder symptoms and urodynamic findings were used
to confirm diagnosis of motor detrusor instability. Patients
were assessed in the clinic after 2, 4, and 6 weeks of
treatment. Study participants completed a 3-day urinary
diary to assess average daily incontinence episodes, a visual
analog scale for efficacy, and an anticholinergic symptoms
questionnaire to determine presence and severity of dry
mouth and other symptoms.
Treatment was initiated at 1 of 3 dosing levels that
matched prior OXY dose requirement. Maximal study doses
were 5.2mg/day TD and 22.5mg/day oral OXY. Double-
blind therapy included daily ingestion of oral OXY, and
twice-weekly application of the TD system (ie, active TD
and placebo oral, or placebo TD and active oral therapy).
The starting dose was continued for the initial 2 weeks,
followed by the investigator-adjusted dose titration based
on the anticholinergic side effect profile. The goal was to
reach the highest tolerable dose, primarily based on dry
mouth severity.
The average number of incontinence episodes was
reduced from washout to end of study by approximately 5
episodes/day in both groups (p<0.0001), with no significant
difference between oral and TD therapy groups.
Visual analog scale analysis revealed no difference in
mean continence score between TD and oral therapy upon
study completion (p=0.9). The change in score for TD and
oral groups from washout to study end was significant
(5.8+4.2 vs 6.0+3.3cm respectively, p<0.0001).
Urodynamics was repeated after dose titration.
Improvements in average bladder volume at first detrusor
contraction were similar with TD and oral treatments
(66+126 vs 45+163ml respectively, p=0.57). Mean
maximum cystometric capacity increased 51+138ml in the
oral (p=0.0538) and 53+88ml in the TD (p=0.0011) groups.
Dry mouth severity was the primary outcome of interest in
this study.
TDOXY vs placebo (Dmochowski et al 2002)
A 12-week, double-blind trial randomized 520 adults with
OAB to receive 3 doses of TDOXY (1.3, 2.6, or 3.9mg) or
placebo twice weekly. A 2-week washout period was allowed
for those receiving pharmacologic treatment. Patients
completed a 7-day urinary diary at baseline, weeks 3, 6, 9,
and 12. The Incontinence Impact Questionnaire (IIQ) and
Urogenital Distress Inventory (UDI) quality of life
instruments were assessed at baseline, and repeated at weeks
6 and 12.
The double-blind period was completed by 447 patients
(86%). Those treated with the 3.9mg/day TD system had a
significant reduction in the number of urinary incontinence
episodes/week compared with placebo (Figure 2). In the
subset of 113 patients previously treated with
anticholinergics, reductions vs placebo were also statistically
significant in the 3.9mg group. Treatment at the lower
dosages did not achieve a statistically significant difference
in weekly incontinence episodes from placebo.
Average daily urinary frequency reduction with this dose
was -2.3+2.5 vs -1.7+3.0 with placebo, p=0.0457. The
median increases in average urinary voided volume were
also better than with placebo (24 vs 6ml, p=0.0063). The
3.9mg group had a significant improvement in the IIQ
quality of life score over placebo, p=0.0327.
The double-blind portion of the trial was followed by a
12-week, open label, dose titration period. It was completed
by 358 (87.1%) of 411 patients who entered the open-label
extension. Patients in all arms experienced reductions from
baseline in the number of incontinence episodes of
approximately 3 episodes/day. The IIQ and UDI also
indicated considerable improvements in quality of life,
specifically with a decrease of 23 points in the Travel domain
(p=0.0018) of the IIQ and a decrease of 25 points in the
Irritative symptoms domain of the UDI, from baseline to
last observation.
Figure 2 Reduction in urge incontinence episodes.Clinical Interventions in Aging 2006:1(2) 102
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TDOXY vs tolterodine and placebo (Dmochowski
et al 2003)
In a double-blind, double-dummy trial of prior responders
to anticholinergic treatment, 361 adults with OAB were
randomized to receive twice-weekly TDOXY 3.9 mg/day,
daily long-acting tolterodine 4mg, or matching placebos for
12 weeks. The median duration of prior treatment was >1
year.
Compared with placebo, there was a significant reduction
in the median number of incontinence episodes with
TDOXY (-3, p=0.0137) and tolterodine (-3, p=0.0011), with
no difference between active treatments (p=0.5878). This
corresponded to a 75% improvement in incontinence
episodes with either tolterodine or TDOXY. Many patients
achieved complete continence (39% with TDOXY, 38% with
tolterodine; both p=0.014 vs placebo).
There was a significant improvement in total IIQ scores
with both active treatments. The Global Assessment of
Disease State scores also improved during TDOXY
(p=0.0106) and tolterodine (p=0.0001) treatments, with no
difference between them (p=0.1861).
Phase 3 clinical trials: combined results
(Dmochowski et al 2005)
The data from two phase 3 trials (Dmochowski et al 2002,
2003) were pooled for further analysis. It included 242
patients who received TDOXY 3.9mg/day, and 245
participants who received placebo. Over 90% of patients
were female and white. Approximately 60% of participants
had been on previous anticholinergic treatment.
Overall, baseline median number of daily incontinence
episodes was 4.0. There was a 75% improvement with
TDOXY treatment, as opposed to a 50% reduction with
placebo (p=0.00004). Likewise, a decrease in daily urinary
frequency was more evident with TDOXY compared with
placebo (18% vs 8.7%, respectively; p=0.0023). There was
a 15% increase in urinary voided volume with TDOXY,
whereas only a 3.6% increase was noted with placebo
(p<0.00001).
Following 12 weeks of treatment, there was a significant
improvement in the mean IIQ quality of life score (-60.7
for TDOXY and -43.0 for placebo, p=0.0182).
Tolerability
TD vs immediate release OXY (Davila et al 2001)
The three most commonly reported anticholinergic adverse
events were reported more commonly in the oral group
compared with the TD group, and included dry mouth (82%
vs 39%), constipation (50% vs 21%), and somnolence (37%
vs 18%). With direct prompted questioning regarding dry
mouth, using the anticholinergic symptoms survey, TD
treatment resulted in 39% of patients recording dry mouth,
as opposed to a 94% incidence with oral treatment, at the
highest tolerable dose (p<0.001). Better tolerability allowed
68% of TD system users to reach the maximum study dose,
compared with only 32% of those in the oral OXY arm
(Figure 3).
During treatment, 38% of TD system users reported an
improvement in constipation, relative to their prior
immediate-release OXY regimen, compared with 5% in the
oral group. Of those receiving a TD application, 61%
revealed no skin erythema.
TDOXY vs placebo (Dmochowski et al 2002)
The most commonly observed treatment-related adverse
events in the double-blind portion were application site
reactions. In the 3.9mg dose group, they included erythema
(5.6%) and pruritus (16.8%). In the open-label extension,
pruritus was the most frequently reported treatment-related
event. The majority of patients experienced no or mild
erythema.
Some patients used topical steroids or antihistamines
(double-blind 4.4%, open-label 1.9% patients). Application
site reactions caused treatment-related withdrawals of some
patients (4.8% in double-blind, 3.6% in open-label
extension).
The most common anticholinergic adverse event for all
doses was dry mouth (7.0% OXY vs 8.3% placebo, p=0.98).
Central nervous system effects occurred infrequently.
Figure 3 Dry mouth tolerability in subjects treated with transdermal
oxybutynin versus immediate-release oxybutynin.Clinical Interventions in Aging 2006:1(2) 103
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TDOXY vs tolterodine and placebo (Dmochowski
et al 2003)
Treatment-related systemic adverse events were more
common with tolterodine, while application site reactions
were more frequent with TDOXY. Erythema (8.3%) and
pruritus (14.0%) were the most common treatment-related
events in the TDOXY group. Dry mouth in this group was
similar to placebo (4.1% vs 1.7%, p=0.2678). With
tolterodine, most common treatment-related events were
anticholinergic effects. Dry mouth in this group was more
frequent than with placebo (7.3% vs 1.7%, p=0.0379).
Phase 3 clinical trials: combined results
(Dmochowski et al 2005)
None of the patients receiving TDOXY discontinued
treatment due to dry mouth; most discontinuations were
because of application site reactions.
Erythema and pruritus was noted in 7.0% (Figure 4) and
16.1% (Figure 5) patients, respectively. Of these, mild-to-
moderate erythema occurred in 71%, and mild-to-moderate
pruritus occurred in 95% patients. Treatment
discontinuations due to erythema were reported by 3.7%,
and due to pruritus by 3.3% patients.
The incidence of application site reactions compares
favorably with that of other studies of TD delivery systems.
These localized, self-limited reactions may be improved in
routine clinical practice through the use of multiple
application sites, including the buttocks and hip areas, in
addition to the abdomen, as used exclusively in the current
trial. Long-term studies suggest that prolonged exposure to
TD systems does not increase the incidence of application
site reactions (Dmochowski et al 2003).
The overall incidence of anticholinergic adverse events
(eg, dry mouth, constipation, dizziness, somnolence,
abnormal vision, nausea) did not differ from placebo (12.8%
vs 11.0%, respectively, p=0.5421).
Patient perceptions
Following the 12-week double-blind portion of the phase 3
trial (Dmochowski et al 2003), patients were eligible to enter
an open-label study extension. These patients could
volunteer to complete a patient satisfaction survey (Newman
2003). A total of 185 questionnaires were analyzed to
measure the satisfaction of using a skin patch for the
treatment of urinary incontinence. Approximately two-thirds
of the participants claimed that if they needed treatment for
incontinence in the future, they would now prefer a TD
system to other treatments.
The majority (72%) of patients reported that the
application site-related itching and redness disappeared
within a week. Many users (68%) described the patch as
very easy to apply. Remembering to reapply the TD system
twice a week was rated as the same as (45%) or easier than
(33%) taking the daily pill.
Future directions
The Multicenter Assessment of Transdermal Therapy in
Overactive Bladder with Oxybutynin (MATRIX) study is a
6-month, open-label, randomized, multicenter, prospective
trial in a community-based population. This study is under
way to assess safety, health-related quality of life, and other
patient-reported outcomes in a large number of patients
treated with TDOXY. Study entry data is already being
reported and providing useful data regarding the current
Figure 4 Skin reactivity of transdermal oxybutynin: erythema.
Figure 5 Skin reactivity of transdermal oxybutynin: pruritus.Clinical Interventions in Aging 2006:1(2) 104
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demographics of the populations of those suffering from
OAB (Sand et al 2005).
Summary and expert opinion
Transdermal OXY presents a safe and effective treatment
modality for patients suffering from OAB. This medication
improves both objective and subjective aspects of OAB,
including an improvement in patient’s quality of life.
Avoidance of first-pass liver metabolism allows for
greater systemic availability of the parent compound, and
diminishes formation of the metabolite, DEO, which is
thought to be associated with anticholinergic side effects.
TDOXY offers efficacy comparable with currently
available oral agents, while its anticholinergic adverse events
profile is comparable with placebo. Most commonly seen
treatment-related side effects are localized application-site
reactions, which are reported as mild–moderate by most
patients who develop erythema or pruritus. Appropriate
patient counseling on healthy skin care, site rotation, prudent
use of topical steroids when appropriate, and avoidance of
local irritants can contribute to the successful incorporation
of TDOXY into the OAB treatment plan.
Transdermal OXY usage in clinical practice has several
limitations. Skin reactivity may pose an insurmountable
barrier for some patients, despite the care recommendations
noted above. Those patients requiring a higher dosage of
OXY may not be able to achieve a clinically satisfactory
response, as the dosage of OXY is related to the patch size.
A dosage requirement of greater than 3.9mg/d would require
a larger patch, or multiple patches, possibly increasing the
rate of skin reactivity and/or making this treatment modality
financially unsuitable. Males may also be less suitable for
patch therapy as the patch needs to be applied to a skin area
devoid of hair. In addition, data is currently unavailable for
pediatric use.
Since becoming Food and Drug Administration-
approved and marketed in 2003, Oxytrol® use has been
associated with various patient-reported beneficial features
not captured in clinical trials. Most are related superficially
to the use of OXY as the therapeutic agent, and many to the
TD patch administration route. Oxybutynin lends itself to
individualization in dosage, both on a chronic basis as well
as for specific short-term usage. Since TD matrix dosing is
dependent on patch surface area, many patients have
increased their dosage by applying an extra patch or a portion
of one (Ruscin et al 2004; Zinner et al 2004). The increased
circulating OXY level can be expected to improve response
rates, based on the previous phase II trial data. Other means
of increasing circulating OXY include taking an oral dosage.
This strategy has been utilized by taking half or one entire
immediate release tablet, immediately prior to an activity
when OAB symptoms would be particularly undesirable,
such as airplane travel or going to a concert or opera. Rarely
has extended-release dosing been used for this purpose.
There have been specialty-related prescriptive patterns
seen for TDOXY. Gynecologists who prescribe matrix-type
patches for hormonal replacement and contraception, have
promptly adopted this agent. Urologists were much less
familiar with patch therapy, having had less than desirable
responses to the reservoir-type patches, and were
significantly slower to adopt this patch.
Since the release of TDOXY, several new oral
anticholinergic agents have become available. Overall
efficacy and response rates for all oral agents are similar,
with specific differences being noted based on particular
study characteristics. The unique pharmacokinetic and
clinical characteristics of TD delivery, including gel and
intravaginal rings currently being clinically evaluated, may
provide additional benefits for OAB sufferers (Figure 6)
(Alberti et al 2005)
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